GILD vs VRTX
GILD and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $211.34B | $144.47B |
| P/E (TTM) | 25.1 | 33.2 |
| P/B | 16.21 | 7.14 |
| P/S | 7.1x | 11.9x |
| Dividend yield | 1.89% | — |
| Revenue | $30.99B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 2.4% | 8.9% |
| Net income | -$3.86B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 1672.9% | 838.1% |
| EPS, diluted | $-3.13(TTM) | $17.17(TTM) |
| EBIT margin | 34.0% | 34.8% |
| ROE | 65.3% | 19.5% |
| ROIC | 25.7% | 25.0% |
| 1y total return | +42.7% | +32.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs VRTX
| Metric | GILD | VRTX |
|---|---|---|
| End value | $29.3K | $64.3K |
| Total return | +192.6% | +543.0% |
| CAGR | +10.9% | +19.7% |
| Volatility | 25.6% | 32.6% |
| Sharpe | 0.37 | 0.59 |
| Sortino | 0.55 | 0.87 |
| Max drawdown | -30.5% | -41.6% |
Based on 2600 common trading days, 2016-06-30 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)